File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Vascular changes in hepatocellular carcinoma

TitleVascular changes in hepatocellular carcinoma
Authors
KeywordsHepatocellular carcinoma
Neoangiogenesis
Vascular endothelial growth factor
Issue Date2008
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/113463905
Citation
Anatomical Record, 2008, v. 291 n. 6, p. 721-734 How to Cite?
AbstractHepatocellular carcinoma (HCC) is one of the most vascular solid tumors, in which angiogenesis plays an important role. The status of angiogenesis in HCC correlates with the disease progression and prognosis, and thus provides a potential therapeutic target. This review summarizes the vascular changes and molecular and cellular basis of angiogenesis in HCC. Development of HCC is characterized by arterialization of its blood supply and sinusoidal capillarization. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that plays a critical role in mediating angiogenesis in HCC. The VEGF can function on various types of cells, such as endothelial cells, hepatic stellate cells, endothelial progenitor cells and hemangiocytes, to induce vascular changes in HCC. Therefore, blockade of VEGF-mediated pathways, either by anti-VEGF neutralizing antibody or tyrosine kinase inhibitors that target VEGF receptors, suppresses carcinogenesis and angiogenesis in HCC. In addition to VEGF, several other angiogenic factors in HCC have recently been identified. These factors can also regulate angiogenic processes through interaction with VEGF or VEGF-independent pathways. Despite the fact that treatment of HCC remains a tough task due to lack of effective systemic therapy, antiangiogenic therapy has already entered clinical trials in HCC patients and sheds light on a promising novel treatment for this disease. © 2008 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/83831
ISSN
2015 Impact Factor: 1.507
2015 SCImago Journal Rankings: 0.778
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYang, ZFen_HK
dc.contributor.authorPoon, RTPen_HK
dc.date.accessioned2010-09-06T08:45:45Z-
dc.date.available2010-09-06T08:45:45Z-
dc.date.issued2008en_HK
dc.identifier.citationAnatomical Record, 2008, v. 291 n. 6, p. 721-734en_HK
dc.identifier.issn1932-8486en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83831-
dc.description.abstractHepatocellular carcinoma (HCC) is one of the most vascular solid tumors, in which angiogenesis plays an important role. The status of angiogenesis in HCC correlates with the disease progression and prognosis, and thus provides a potential therapeutic target. This review summarizes the vascular changes and molecular and cellular basis of angiogenesis in HCC. Development of HCC is characterized by arterialization of its blood supply and sinusoidal capillarization. Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that plays a critical role in mediating angiogenesis in HCC. The VEGF can function on various types of cells, such as endothelial cells, hepatic stellate cells, endothelial progenitor cells and hemangiocytes, to induce vascular changes in HCC. Therefore, blockade of VEGF-mediated pathways, either by anti-VEGF neutralizing antibody or tyrosine kinase inhibitors that target VEGF receptors, suppresses carcinogenesis and angiogenesis in HCC. In addition to VEGF, several other angiogenic factors in HCC have recently been identified. These factors can also regulate angiogenic processes through interaction with VEGF or VEGF-independent pathways. Despite the fact that treatment of HCC remains a tough task due to lack of effective systemic therapy, antiangiogenic therapy has already entered clinical trials in HCC patients and sheds light on a promising novel treatment for this disease. © 2008 Wiley-Liss, Inc.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/113463905en_HK
dc.relation.ispartofAnatomical Recorden_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectNeoangiogenesisen_HK
dc.subjectVascular endothelial growth factoren_HK
dc.titleVascular changes in hepatocellular carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ar.20668en_HK
dc.identifier.scopuseid_2-s2.0-45849135992en_HK
dc.identifier.hkuros142900en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-45849135992&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume291en_HK
dc.identifier.issue6en_HK
dc.identifier.spage721en_HK
dc.identifier.epage734en_HK
dc.identifier.isiWOS:000256718800013-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYang, ZF=14018809600en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.citeulike6128648-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats